Please assess the completion status of the following clinical trial:

Trial Title: Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with primary OA in target knee by American College of Rheumatology (ACR) criteria~* Screening pain criteria sufficient as assessed by WOMAC and VAS scores~* Ability to read and understand the informed consent~Exclusion Criteria:~* Women who are pregnant or lactating or child bearing potential, men must use a barrier method of contraception~* Any condition, including laboratory findings, that in the opinion of the investigator constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct or evaluation~* Body mass index \>40~* Major knee surgery in the target knee within 12 months prior to study or planned surgery during the study period~* History of malignancy within the last 5 years~* Participation in a clinical research trial within 12 weeks prior~* Treatment of the target knee with intra-articular steroids within 2 months or hyaluronic acid derivatives within 6 months~* Effusion of the target knee requiring aspiration within 3 months~* Use of electrotherapy or acupuncture for OA within 4 weeks~* Significant and clinically evident misalignment of the target knee~* Any known active infections~* Any chronic condition that has not been well controlled for a minimum of 3 months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SM04690, 0.03mg/2mL (Type: EXPERIMENTAL): Single, intra-articular injection of SM04690, 0.03mg/2mL
- SM04690, 0.07mg/2mL (Type: EXPERIMENTAL): Single, intra-articular injection of SM04690, 0.07mg/2mL
- SM04690, 0.23mg/2mL (Type: EXPERIMENTAL): Single, intra-articular injection of SM04690, 0.23mg/2mL
- Placebo (Type: PLACEBO_COMPARATOR): Single, intra-articular injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).